Clinical Trial

A Study to Evaluate MWN109 Tablets in Healthy Adult Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 20, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single-and-multiple ascending dose study in which the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of orally administered MWN109 tablets will be assessed in healthy adult participants.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-14; most recent amendment 2025-11-17.
Status change: Not Yet Recruiting → Recruiting 2025-11-17
Trial Details
NCT Number NCT06938269
Lead Sponsor Shanghai Minwei Biotechnology Co., Ltd
Conditions Overweight or Obesity
Enrollment 60 participants
Start Date 2025-06-18
Primary Completion 2026-03 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2025-11-20